Elevated Midkine Serum Levels Are Associated with Long-Term Survival in Critically Ill Patients

Int J Mol Sci. 2023 Dec 29;25(1):454. doi: 10.3390/ijms25010454.

Abstract

Midkine (Mdk) is a multifunctional protein involved in inflammatory processes. Hence, circulating Mdk is increased in sepsis and has been previously suggested as a potential biomarker in these patients. The aim of this study was to elucidate the role of Mdk serum concentrations in critical illness and sepsis and to verify its value as a prognostic biomarker. Thus, we analyzed the Mdk serum concentrations of 192 critically ill patients on admission to the medical intensive care unit (ICU). While the serum levels of Mdk at admission were similar in septic and nonseptic critical illness (362 vs. 337 ng/L, p = 0.727), we found several interesting correlations of Mdk to laboratory and clinical markers associated with ischemia or hypoxia, e.g., to renal failure and hepatic injury. Mdk serum concentrations at admission did not differ between various causes of sepsis or other critical illness. Most noticeable, we observed upregulated Mdk serum concentrations at admission in patients surviving in the long-term, which was only seen in nonseptic critical illness but not in sepsis. Our study suggests a relevant role of Mdk in critically ill patients in general and highlights the possible protective features of Mdk in critical illness.

Keywords: Midkine; biomarker; critical illness; human; immune system; inflammation; intensive care unit; mortality; prognosis; sepsis; survival.

MeSH terms

  • Biomarkers
  • Critical Illness*
  • Hospitalization
  • Humans
  • Midkine
  • Sepsis*

Substances

  • Biomarkers
  • Midkine
  • MDK protein, human